NAPLES, Fla., Dec. 31, 2020 /PRNewswire/ -- Enveric
Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the
"Company"), formerly AMERI Holdings, Inc. (NASDAQ:
AMRH), a patient-centric biotechnology company endeavoring to
enhance the lives of those who are adversely affected by the side
effects of Cancer Treatments with novel cannabinoid medicines,
announced the completion of the previously announced spin-off of
the IT services business of the Company and the tender offer,
whereby the Company purchased all of the outstanding common shares
of Jay Pharma Inc. ("Jay Pharma") in exchange for shares of Company
common stock, or if applicable, shares of Company preferred stock.,
and Jay Pharma became a wholly-owned subsidiary of the Company.
The Company has also completed its name change from AMERI
Holdings, Inc. to Enveric Biosciences, Inc., and has effected a
1-for-4 reverse split of its common stock, effective as of
4:02 pm Eastern Time, December 30, 2020. Enveric will commence trading
on the Nasdaq Capital Market at the opening of trading this
morning, December 31, 2020, under its
new ticker symbol "ENVB" on a post-reverse-stock-split basis (CUSIP
No. 29405E 109).
"We are thrilled to complete this transaction and commence
trading on the Nasdaq as Enveric Biosciences under the ticker
symbol "ENVB." Today marks the beginning of our journey as a
publicly traded company, enhancing the visibility of our business
to the investment community. The support of existing and new
investors will enable us to continue our dedicated work of
developing innovative treatments focused on the unmet need for
supportive care of cancer patients by adding life to patients'
years, not just years to their lives," said David Johnson, Chairman and CEO at Enveric
Palladium Capital Group, LLC acted as financial advisor to
the parties in connection with the above transactions.
Additional information regarding the foregoing transactions and
the reverse stock split, which were approved at the special
meeting of Company stockholders held on December 29, 2020, can be found in the Company's
definitive proxy/prospectus and other relevant documents filed with
the Securities and Exchange Commission ("SEC") at the SEC's
website at www.sec.gov.
Copies of the documents filed by the Company with the SEC are
available free of charge on the Company's website at
www.enveric.com or by contacting Company Investor Relations.
About Enveric Biosciences
is a patient-centric biotechnology company endeavoring to enhance
the lives of those who are adversely affected by the side effects
of Cancer Treatments. Enveric has set out with the goal of
rigorously testing natural compounds, starting with cannabinoids,
to provide patients and clinicians with novel prescription
medicines to serve these unmet medical needs.
For more information, please visit https://www.enveric.com/.
This press release contains forward-looking statements and
forward-looking information within the meaning of applicable
securities laws. These statements relate to future events or future
performance. All statements other than statements of historical
fact may be forward-looking statements or information. Generally,
forward-looking statements and information may be identified by the
use of forward-looking terminology such as "plans", " expects" or
"does not expect", "proposed", "is expected", "budgets",
"scheduled", "estimates", "forecasts", "intends", "anticipates" or
"does not anticipate", or "believes", or variations of such words
and phrases, or by the use of words or phrases which state that
certain actions, events or results may, could, would, or might
occur or be achieved. Forward-looking statements consist of
statements that are not purely historical, including any statements
regarding beliefs, plans, expectations or intentions regarding the
future. Readers are cautioned not to place undue reliance on
forward-looking statements, as there can be no assurance that the
Amalgamation will be consummated or that the parties other plans,
intentions or expectations upon which they are based will occur. By
their nature, forward-looking statements involve numerous
assumptions, known and unknown risks and uncertainties, both
general and specific that contribute to the possibility that the
predictions, estimates, forecasts, projections and other
forward-looking statements will not occur.
The forward-looking statements contained in this press release
are made as of the date of this press release. Except as required
by law, the Company disclaims any intention and assumes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Additionally, the Company undertakes no obligation to comment on
the expectations of, or statements made by, third parties in
respect of the matters discussed above.
Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
SOURCE Enveric Biosciences